n Cardiovascular Journal of South Africa - PROactive study shows reduced heart attacks and strokes in type 2 diabetics on pioglitazone HCI (Actos®) therapy : drug trends




The ambitious PROactive study, initiated in 2001, is the first prospective, randomised, double-blind, placebo-controlled trial of an oral glucose-lowering medication's ability to significantly improve cardiovascular outcomes over 2.5 years of therapy in type 2 diabetics. The study added pioglitazone to the treatment of type 2 diabetics who were already receiving standard-care therapy including dietary modification, glucose lowering (using metformin, sulphonylureas and insulin), blood pressure regulation, lipid lowering and antithrombotic agents, according to the 1999 IDF (European) guidelines.


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error